Microneedle array patches for sustained delivery of fluphenazine: A micron scale approach for the management of schizophrenia
Source abstract
Abstract
Schizophrenia is a severe chronic mental illness characterised by impaired emotional and cognitive functioning. To treat this condition, antipsychotics are available in limited dosage forms, mainly oral and injectable formulations. Although injectable antipsychotics were designed to enhance adherence, they are invasive, painful and require a healthcare professional to be administered. To overcome such administration issues, extensive research has been focused on developing transdermal antipsychotic formulations. In this work, three microneedle (MN) systems were developed to deliver fluphenazine (FLU) systemically. A decanoic prodrug of FLU called fluphenazine decanoate (FLUD) was used in two of the MN formulations due to its high lipophilicity. FLU-D was loaded into dissolving MNs and nanoemulsion (NE)-loaded MNs. The parent drug FLU was loaded into poly(lactic-co-glycolic acid) (PLGA)-tipped MNs. All MN systems were characterised and evaluated in vitro and in vivo. The in vivo evaluation of the three developed MN systems showed their ability to deliver FLU into the systemic circulation, as the Cmax of FLU-D dissolving MNs was 36.11 ± 12.37 ng/ml. However, the Cmax of FLU-D NE loaded dissolving MNs was 12.92 ± 6.3 ng/ml and for FLU-PLGA tipped MNs was 21.57 ± 2.45 ng/ml. Compared to an intramuscular (IM) injection of FLU-D in sesame oil, the relative bioavailabilities were 26.96 %, 21.73 % and 42.45 % for FLU-D dissolving MNs, FLU-D NE dissolving MNs and FLU-PLGA tipped MNs, respectively. FLU plasma levels were maintained above the minimum human therapeutic limits for a week. Consequently, these various MN formulations are considered to be a viable options for the transdermal delivery of fluphenazine and its prodrug. The three MN systems developed offer patients a user-friendly, painless, and convenient long-acting delivery method for FLU. Reducing dosing frequency and using less invasive drug administration methods can enhance adherence and foster positive therapeutic outcomes. This study demonstrates the capability and adaptability of MNs technology to transport hydrophobic molecules from the skin to the systemic circulation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Ocular Surface and Contact Lens · Dermatology and Skin Diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (92)
Show source-provided references
1. Schizophrenia and abnormal brain network hubs10.31887/DCNS.2013.15.3/mrubinov ↗
2. The diagnostic concept of schizophrenia: its history, evolution, and future prospects10.31887/DCNS.2010.12.3/ajablensky ↗
3. Global economic burden of schizophrenia: a systematic review
4. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis10.1001/jamapsychiatry.2014.2502 ↗
5. Practice guideline for the treatment of patients with schizophrenia, second edition
6. 3d-printed implantable devices with biodegradable rate-controlling membrane for sustained delivery of hydrophobic drugs10.1080/10717544.2022.2057620 ↗
7. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review10.1177/2045125312474019 ↗
8. Relapse in schizophrenia: costs, clinical outcomes and quality of life10.1192/bjp.184.4.346 ↗
9. The cost of relapse in schizophrenia10.1007/s40273-017-0515-3 ↗
10. Transdermal delivery of antipsychotics: rationale and current status10.1007/s40263-019-00659-7 ↗
11. Long-acting parenteral drug delivery systems for the treatment of chronic diseases10.1016/j.addr.2023.114862 ↗
12. Zero order controlled release delivery of cholecalciferol from injectable biodegradable microsphere: in-vitro characterization and in-vivo pharmacokinetic studies10.1016/j.ejps.2017.06.027 ↗
13. Long-acting microspheres of human chorionic gonadotropin hormone: in-vitro and in-vivo evaluation10.1016/j.ijpharm.2021.121312 ↗
14. Development and evaluation of dissolving microarray patches for co-administered and repeated intradermal delivery of long-acting rilpivirine and cabotegravir nanosuspensions for paediatric HIV antiretroviral therapy
15. Novel bilayer microarray patch-assisted long-acting micro-depot cabotegravir intradermal delivery for HIV pre-exposure prophylaxis
16. Prediction of corresponding dose of transdermal blonanserin to oral dose based on dopamine d2 receptor occupancy: unique characteristics of blonanserin transdermal patch10.1097/JCP.0000000000001545 ↗
17. Delivery of nanomedicines using microneedles
18. Novel fluphenazine decanoate nanoemulsion loaded dissolving microneedles for transdermal delivery
19. Why drug delivery is the key to new medicines10.1038/s41591-022-01826-y ↗
20. Directly compressed tablets: a novel drug-containing reservoir combined with hydrogel-forming microneedle arrays for transdermal drug delivery10.1002/adhm.202001256 ↗
21. Trilayer dissolving polymeric microneedle array loading Rose Bengal transfersomes as a novel adjuvant in early-stage cutaneous melanoma management10.1016/j.ijpharm.2022.122217 ↗
22. Pullulan-based dissolving microneedle arrays for enhanced transdermal delivery of small and large biomolecules10.1016/j.ijbiomac.2019.12.184 ↗
23. Localised and sustained intradermal delivery of methotrexate using nanocrystal-loaded microneedle arrays: potential for enhanced treatment of psoriasis10.1016/j.ejps.2020.105469 ↗
24. Microneedle array systems for long-acting drug delivery10.1016/j.ejpb.2020.12.006 ↗
25. Hydrogel-forming microarray patches with solid dispersion reservoirs for transdermal long-acting microdepot delivery of a hydrophobic drug10.1016/j.jconrel.2023.03.003 ↗
26. Ring inserts as a useful strategy to prepare tip-loaded microneedles for long-acting drug delivery with application in HIV pre-exposure prophylaxis10.1016/j.matdes.2022.111416 ↗
27. Dissolving microneedle patches loaded with amphotericin B microparticles for localised and sustained intradermal delivery: potential for enhanced treatment of cutaneous fungal infections10.1016/j.jconrel.2021.10.001 ↗
28. Versatility of hydrogel-forming microneedles in in vitro transdermal delivery of tuberculosis drugs10.1016/j.ejpb.2020.12.003 ↗
29. Novel tip-loaded dissolving and implantable microneedle array patches for sustained release of finasteride10.1016/j.ijpharm.2021.120885 ↗
30. Artemether and lumefantrine dissolving microneedle patches with improved pharmacokinetic performance and antimalarial efficacy in mice infected with Plasmodium yoelii10.1016/j.jconrel.2021.03.036 ↗
31. Dissolving polymeric microneedle arrays for enhanced site-specific acyclovir delivery10.1016/j.ejps.2018.05.009 ↗
32. Hollow microneedle assisted intradermal delivery of hypericin lipid nanocapsules with light enabled photodynamic therapy against skin cancer
33. Fluphenazeve decanoate10.1016/S0099-5428(08)60144-6 ↗
34. Sensitive method for the simultaneous measurement of fluphenazine decanoate and fluphenazine in plasma by high-performance liquid chromatography with cuolometric detection10.1016/S0378-4347(96)00287-3 ↗
35. HPLC-MS method for simultaneous quantification of the antiretroviral agents rilpivirine and cabotegravir in rat plasma and tissues10.1016/j.jpba.2022.114698 ↗
36. Nanoemulsion-based dissolving microneedle arrays for enhanced intradermal and transdermal delivery10.1007/s13346-021-01107-0 ↗
37. A review on novel emulsification technique: a nanoemulsion, research & reviews
38. Long-acting nanoparticle-loaded bilayer microneedles for protein delivery to the posterior segment of the eye10.1016/j.ejpb.2021.05.022 ↗
39. Nanosuspension-loaded dissolving bilayer microneedles for hydrophobic drug delivery to the posterior segment of the eye10.1016/j.bioadv.2022.212767 ↗
40. Poly (caprolactone)-based subcutaneous implant for sustained delivery of levothyroxine10.1016/j.ijpharm.2021.121011 ↗
41. Hydrogel-forming microneedles for rapid and efficient skin deposition of controlled release tip-implants10.1016/j.msec.2021.112226 ↗
42. Nanosuspension-based dissolving microneedle arrays for intradermal delivery of curcumin10.3390/pharmaceutics11070308 ↗
43. Two-photon polymerisation 3D printing of microneedle array templates with versatile designs: application in the development of polymeric drug delivery systems10.1007/s11095-020-02887-9 ↗
44. Enhancing intradermal delivery of tofacitinib citrate: comparison between powder-loaded hollow microneedle arrays and dissolving microneedle arrays10.1016/j.ijpharm.2020.120152 ↗
45. Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery10.1016/j.jconrel.2020.03.026 ↗
46. Fluphenazine (oral) versus placebo for schizophrenia
47. Understanding depot antipsychotics: an illustrated guide to kinetics10.1017/S1092852913000783 ↗
48. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats10.1016/j.colsurfb.2013.12.016 ↗
49. Nanoemulsion: concepts, development and applications in drug delivery10.1016/j.jconrel.2017.03.008 ↗
50. The role of the lymphatic system in the presystemic absorption of fluphenazine after intramuscular administration of fluphenazine decanoate in rats10.1016/0928-0987(94)00070-G ↗
51. Nanoemulsion: an emerging technology for oilfield applications between limitations and potentials10.1016/j.petrol.2021.109306 ↗
52. Nanoemulsion-based dissolving microneedle arrays for enhanced intradermal and transdermal delivery
53. Nanoemulsion as pharmaceutical carrier for dermal and transdermal drug delivery: formulation development, stability issues, basic considerations and applications10.1016/j.jconrel.2017.11.049 ↗
54. Fabrication and evaluation of quercetin nanoemulsion: a delivery system with improved bioavailability and therapeutic efficacy in diabetes mellitus10.3390/ph15010070 ↗
55. Interfacial and colloidal properties of emulsified systems: pharmaceutical and biological perspective
56. Transdermal delivery of second-generation antipsychotics for management of schizophrenia; disease overview, conventional and nanobased drug delivery systems10.1016/j.jddst.2020.102104 ↗
57. Investigation of antimicrobial properties of sage essential oil and its nanoemulsion as antimicrobial agent10.1016/j.lwt.2020.109669 ↗
58. Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe10.1016/j.colsurfb.2009.11.021 ↗
59. Multiobjective optimization of fluphenazine nanocomposite formulation using nsga-ii method10.2478/msp-2021-0042 ↗
60. Fluphenazine release from biodegradable microparticles: characterization and modelling of release10.1080/02652040802396575 ↗
61. Novel nanosuspension-based dissolving microneedle arrays for transdermal delivery of a hydrophobic drug10.1002/jin2.41 ↗
62. Design of experiments for the development of injectable drug products
63. Self-assembled nanocomplexes of anionic pullulan and polyallylamine for DNA and pH-sensitive intracellular drug delivery10.1007/s11051-014-2781-8 ↗
64. Preparation, characterization, and evaluation of antioxidant activity and bioavailability of a self-nanoemulsifying drug delivery system (snedds) for buckwheat flavonoids10.1093/abbs/gmaa124 ↗
65. Rapidly dissolving microneedles for the delivery of cubosome-like liquid crystalline nanoparticles with sustained release of rapamycin10.1016/j.ijpharm.2020.119942 ↗
66. Drug delivery by Micro, Nanoemulsions in tuberculosis
67. Development and characterization of nanoemulsion as carrier for the enhancement of bioavailability of artemether10.3109/21691401.2014.887018 ↗
68. Multifunctional low temperature-cured PVA/PVP/citric acid-based hydrogel forming microarray patches: physicochemical characteristics and hydrophilic drug interaction10.1016/j.eurpolymj.2023.111836 ↗
69. Nestorone nanosuspension-loaded dissolving microneedles array patch: a promising novel approach for “on-demand” hormonal female-controlled peritcoital contraception10.1016/j.ijpharm.2021.121422 ↗
70. Etravirine-loaded dissolving microneedle arrays for long-acting delivery10.1016/j.ejpb.2021.04.024 ↗
71. Deferasirox nanosuspension loaded dissolving microneedles for intradermal delivery10.3390/pharmaceutics14122817 ↗
72. Microarray patch delivery of long-acting HIV PrEP and contraception
73. Microneedle characterisation: the need for universal acceptance criteria and gmp specifications when moving towards commercialisation10.1007/s13346-015-0237-z ↗
74. Hydrogel-forming microneedles for rapid and efficient skin deposition of controlled release tip-implants10.1016/j.msec.2021.112226 ↗
75. Enzyme-catalyzed activation of anticancer prodrugs10.1124/pr.56.1.3 ↗
76. Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil10.1023/A:1012165731390 ↗
77. Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat10.1016/0893-133X(95)00070-T ↗
78. Siragusa · 2022
79. Enzyme-triggered l-α/d-peptide hydrogels as a long-acting injectable platform for systemic delivery of HIV/AIDS drugs
80. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension10.1016/j.jconrel.2018.11.002 ↗
81. Assessment of pharmacologic area under the curve when baselines are variable10.1007/s11095-010-0363-8 ↗
82. Solid lipid nanoparticle-based dissolving microneedles: a promising intradermal lymph targeting drug delivery system with potential for enhanced treatment of lymphatic filariasis10.1016/j.jconrel.2019.10.004 ↗
83. Long-lasting drug delivery systems based on microneedles
84. A comparison of dissolving microneedles and transdermal film with solid microneedles for iloperidone in vivo: a proof of concept, Naunyn-Schmiedeberg’s10.1007/s00210-022-02309-0 ↗
85. Antipsychotics-loaded nanometric emulsions for brain delivery10.3390/pharmaceutics14102174 ↗
86. Nanotechnological advances for nose to brain delivery of therapeutics to improve the Parkinson therapy
87. Hollow microneedles: a perspective in biomedical applications10.1016/j.ijpharm.2021.120455 ↗
88. The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis10.1016/j.addr.2021.06.002 ↗
89. Hydrogel-forming microarray patches with cyclodextrin drug reservoirs for long-acting delivery of poorly soluble cabotegravir sodium for HIV pre-exposure prophylaxis10.1016/j.jconrel.2022.06.028 ↗
90. Development and characterisation of novel poly (vinyl alcohol)/poly (vinyl pyrrolidone)-based hydrogel-forming microneedle arrays for enhanced and sustained transdermal delivery of methotrexate10.1016/j.ijpharm.2020.119580 ↗
91. Solid implantable devices for sustained drug delivery10.1016/j.addr.2023.114950 ↗
92. Development of dissolving microneedles for intradermal delivery of the long-acting antiretroviral drug bictegravir10.1016/j.ijpharm.2023.123108 ↗